The #ObesityMedicineAssociation, along with #TheObesitySociety, #AmericanCollegeofLifestyleMedicine, and #AmericanSocietyforNutrition, has published a joint advisory, Nutritional Priorities to Support GLP-1 Therapy for Obesity, providing clinicians with evidence-based recommendations
April - June 2022 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
Key highlights Both semaglutide and dulaglutide are GLP-1 medications with the same mechanism of action
Always consult a qualified healthcare provider before using any semaglutide product, and obtain prescriptions only for FDA-approved medications from licensed pharmacies
For listing of glutathione system genes based on sequence analysis, RPS-Blast with NCBI Protein clusters database (ProtClustDB) [17] was used